Study S003259

A Phase II Trial Comparing Efficacy and Safety of GZR101 and Insulin Degludec/Insulin Aspart in Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drug (OAD) Therapy or OAD Therapy in Combination with Insulin

ClinicalTrials.gov record

Registration

Registration: NCT06199505
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: NONE
Status: COMPLETED
Enrollment: 153
Start: 2023-11-21
Primary completion: 2024-06-28
Lead sponsor: Gan and Lee Pharmaceuticals, USA
Conditions: Type 2 Diabetes
Interventions: DRUG:GZR101; DRUG:insulin degledec/insulin aspart
Results posted: FALSE

Registered primary outcomes

Change in HbA1c [Baseline to week 16]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.